Should I Buy MDBH? MDBH 2026 Analysis

Should You Buy MDB Capital Holdings LLC (MDBH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

3.210

1 Day change

3.22%

52 Week Range

7.980

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: trend is bearish (SMA_200 > SMA_20 > SMA_5) and momentum remains negative (MACD histogram below 0).
Intellectia Proprietary Trading Signals are absent (no AI Stock Picker or SwingMax entry), removing the main “strong buy” triggers.
Fundamentals are weak in the latest reported quarter (2025/Q3) with sharp YoY revenue decline and deeper losses; this does not fit an impatient “buy now” approach.
News is mildly positive (board appointment) but not a clear near-term earnings/cash-flow catalyst.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), suggesting price is below key longer-term trend measures.
Momentum: MACD histogram at -0.0265 (below zero) and negatively contracting—bearish momentum persists, though selling pressure may be moderating.
RSI (6): 41.35, neutral-to-weak; not oversold enough to imply a high-conviction bounce.
Levels:
- Pivot: 3.247 (price 3.14 is below pivot, a bearish tell).
- Support: S1 3.064 then S2 2.95 (a break below 3.064 increases downside risk).
- Resistance: R1 3.43 then R2 3.544 (needs reclaim to improve short-term setup).
Pattern-based forward drift (from similar candlesticks): slightly negative bias over week/month (-1.95% next week, -0.19% next month).

Positive Catalysts

- Board refresh: Appointment of Jeb Terry (microcap medical/biotech investing background) could help sourcing deals and credibility within targeted sectors.
- Strategic messaging: Management reiterates focus on public venture capital platform and early public offerings/follow-on financings—potentially supportive if capital markets window improves.

Neutral/Negative Catalysts

- Price/Trend risk: Bearish moving average stack and sub-pivot trading suggests rallies may face resistance.
- Weak near-term statistical outlook: pattern-based probabilities lean slightly negative over the next week.
- No identifiable event-driven upside catalyst in the news beyond governance/board changes.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 1,250,892, down sharply YoY (-303.65% as provided), indicating major top-line deterioration versus prior year period.
Net income: -4,656,811 (loss widened vs prior year as indicated by -39.80% YoY in the dataset).
EPS: -0.46 (down -44.58% YoY), showing profitability per share is worsening.
Overall: Growth trend is negative with continued losses—does not support an aggressive “buy now” stance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so a current Wall Street pros/cons consensus view cannot be confirmed from the dataset.
Practical takeaway: absent published coverage/targets here, the decision must lean more heavily on price action + fundamentals, both of which skew negative at the moment.

Analyst Rating

Wall Street analysts forecast MDBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDBH is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold